Nektar Therapeutics | NKTR - Stock


Nektar Therapeutics reported $14.46M in Stock for its fiscal quarter ending in June of 2024.





Stock Change Date
Agios Pharmaceuticals USD 35.75M 665K Jun/2026
ALKERMES USD 298.96M 37.75M Jun/2026
Amgen USD 6.22B 34M Jun/2026
Baxter International USD 2.26B 57M Jun/2026
BioCryst Pharmaceuticals USD 6.06M 71K Jun/2026
Biogen USD 2.38B 435.3M Jun/2026
Bristol-Myers Squibb USD 2.74B 19M Jun/2026
Cara Therapeutics USD 900K 0 Mar/2025
Cipla INR 65.97B 4.37B Mar/2026
Dr.Reddys Laboratories INR 80.47B 3.94B Jun/2026
Eisai JPY 257.55B 21.09B Mar/2026
Eli Lilly USD 16.79B 2.26B Jun/2026
Exelixis USD 28.73M 2.12M Jun/2026
Gilead Sciences USD 1.91B 140M Mar/2026
GlaxoSmithKline GBP 6.16B 233M Mar/2026
Grifols EUR 3.56B 63.19M Dec/2024
Halozyme Therapeutics USD 137.14M 18.33M Jun/2026
Incyte USD 112.54M 3.08M Jun/2026
Ionis Pharmaceuticals USD 50.83M 45.28M Jun/2026
Karyopharm Therapeutics USD 4.04M 72K Dec/2025
MacroGenics USD 9.5M 1.59M Mar/2026
Merck USD 6.21B 272M Jun/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 104.2M 39.7M Jun/2026
Novartis USD 6.22B 66M Jun/2026
Pfizer USD 9.94B 722M Jun/2026
Roche Holding CHF 7.6B 9M Jun/2025
Sarepta Therapeutics USD 904.27M 96.84M Jun/2026
Takeda JPY 1.45T 50.64B Jun/2026
Teva Pharmaceutical Industries USD 3.18B 3M Mar/2026